https://www.selleckchem.com/pr....oducts/cct251545.htm
The development of CRISPR/Cas9-PLGA-NPs provides an attractive tool for the delivery of the CRISPR components to target HSPCs, and could provide the basis for in vivo treatment of hemoglobinopathies and other genetic diseases.Pathogenic microbes can cause infections or diseases in hosts and they pose ongoing threats to human health. Antibiotics have been taken an active role in treating a wide variety of infections or diseases since they were first introduced in the 1940s. However, the emergence of antibiotic-resistant microbes makes

https://www.selleckchem.com/products/scr7.html
Dendritic cells (DCs) possess intrinsic cellular defense mechanisms to specifically inhibit HIV-1 replication. In turn, HIV-1 has evolved strategies to evade innate immune sensing by DCs resulting in suboptimal maturation and poor antiviral immune responses. We previously showed that complement-opsonized HIV-1 (HIV-C) was able to efficiently infect various DC subsets significantly higher than non-opsonized HIV-1 (HIV) and therefore also mediate a higher antiviral immunity. Thus, complement coating of HIV-1 might play a role with respect to